Billboard rules baffles DDMAC

Share this article:
“How does the FDA regard signage or billboards advertising pharmaceutical products that are prominently displayed at ballparks and other sports stadiums, and which may be viewed by tens of thousands or even millions of sports fans at televised events? Does such signage come under FDA's authority ... ?” 

This intriguing question from the audience seemed to stump a panel of FDA staffers at the DTC National Conference in Washington in April.

After a pause, Division of Drug Marketing, Advertising, and Communications reviewer Kathryn Aikin spoke for the panel: “Honestly, I don't know the answer to that question. I'm not sure we've ever thought about it. But we'll discuss it back at the office.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...